[{"orgOrder":0,"company":"Kyongbo Pharmaceutical Co., Ltd","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kyongbo Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Kyongbo Pharmaceutical Co., Ltd","sponsor":"Seoul National University Hospital","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"SOUTH KOREA","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Undisclosed","graph3":"Kyongbo Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Undisclosed","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Intravenous","sponsorNew":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"1","companyTruncated":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd"},{"orgOrder":0,"company":"Kyongbo Pharmaceutical Co., Ltd","sponsor":"Kyongbo Pharmaceutical Co., Ltd","pharmaFlowCategory":"DU","therapeuticArea":"Neurology","country":"","productType":"Other Small Molecule","year":"2023","type":"Inapplicable","leadProduct":"Paracetamol","moa":"Vanilloid receptor | Anandamide amidohydrolase | Cyclooxygenase","graph1":"Neurology","graph2":"Phase IV","graph3":"Kyongbo Pharmaceutical Co., Ltd","amount2":0,"highestDevelopmentShortName":"Ph IV","therapeuticAreaShortName":"Neurology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd","highestDevelopmentStatusID":"11","companyTruncated":"Kyongbo Pharmaceutical Co., Ltd \/ Kyongbo Pharmaceutical Co., Ltd"}]

Find Clinical Drug Pipeline Developments & Deals by Kyongbo Pharmaceutical Co., Ltd

Menu
Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          April 28, 2023

                          Lead Product(s) : Paracetamol

                          Therapeutic Area : Neurology

                          Highest Development Status : Phase IV

                          Recipient : Korea University Guro Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 17, 2023

                          Lead Product(s) : Paracetamol

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Recipient : Seoul National University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          03

                          Peptide Process CMC
                          Not Confirmed
                          Peptide Process CMC
                          Not Confirmed

                          Details : Undisclosed

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          May 09, 2022

                          Lead Product(s) : Paracetamol

                          Therapeutic Area : Neurology

                          Highest Development Status : Undisclosed

                          Recipient : Seoul National University Hospital

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank